| Literature DB >> 35246059 |
Nan Gao1,2, Xiaoyong Qi3,4, Yi Dang5, Yingxiao Li5, Gang Wang6, Xiao Liu5, Ning Zhu2, Jinguo Fu6.
Abstract
BACKGROUND: Symptom-to-balloon time (SBT) represents the total ischemic time in ST-elevated myocardial infarction (STEMI) and is associated with poor long-term outcomes. The study aimed to explore the association between SBT and in-hospital mortality after emergency percutaneous coronary intervention (PCI) in patients with acute STEMI.Entities:
Keywords: Ischemia time; Percutaneous coronary intervention; ST-elevated myocardial infarction; Symptom-to-balloon time
Mesh:
Year: 2022 PMID: 35246059 PMCID: PMC8896149 DOI: 10.1186/s12872-022-02526-8
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
General characteristics of subjects with the number of EF < 50%
| Characteristic | SBT (minutes) | ||||
|---|---|---|---|---|---|
| ≤ 120 | 121–240 | 241–360 | ≥ 361 | ||
| (n = 31) | (n = 130) | (n = 126) | (n = 92) | ||
| Male, n (%) | 25 (80.6) | 101 (77.7) | 98 (77.8) | 70 (76.1) | 0.96 |
| Smoking history, n (%) | 19 (61.3) | 65 (50.0) | 55 (43.7) | 39 (42.4) | 0.23 |
| Drinking history, n (%) | 12 (38.7) | 33 (25.4) | 34 (27.0) | 7 (7.6) | 0.5 |
| DM history, n (%) | 2 (6.5) | 30 (23.1) | 29 (23.0) | 20 (21.7) | 0.21 |
| Hypertension history, n (%) | 14 (45.2) | 54 (41.5) | 50 (39.7) | 50 (54.3) | 0.15 |
| Myocardial infarction history, n (%) | 1 (3.2) | 12 (9.2) | 13 (10.3) | 8 (8.7) | 0.67 |
| Atrial fibrillation history, n (%) | 1 (3.2) | 2 (1.5) | 3 (2.4) | 3 (3.2) | 0.85 |
| I | 23 (74.2) | 100 (76.9) | 102 (81.0) | 59 (64.1) | 0.04 |
| II | 7 (22.6) | 23 (17.7) | 11 (8.7) | 15 (16.3) | 0.1 |
| III | 1 (3.2) | 3 (2.3) | 6 (4.8) | 4 (4.4) | 0.74 |
| IV | 0 (0) | 4 (3.1) | 7 (5.5) | 14 (15.2) | 0.001 |
| LM, n (%) | 0 (0) | 1 (0.8) | 1 (0.8) | 4 (4.3) | 0.11 |
| LAD, n (%) | 20 (64.5) | 77 (59.2) | 70 (55.6) | 47 (51.1) | 0.5 |
| LCX, n (%) | 2 (6.5) | 13 (10.0) | 10 (7.9) | 13 (14.1) | 0.43 |
| RCA, n (%) | 9 (29.0) | 39 (30.0) | 45 (35.7) | 30 (32.6) | 0.77 |
| 0 | 0 (0) | 1 (0.8) | 0 (0) | 0 (0) | 0.59 |
| 1 | 0 (0) | 1 (0.8) | 0 (0) | 1 (1.1) | 0.67 |
| 2 | 2 (6.5) | 10 (7.7) | 10 (7.9) | 6 (6.5) | 0.97 |
| 3 | 9 (29.0) | 55 (42.3) | 53 (42.1) | 42 (45.7) | 0.45 |
| 4 | 18 (58.1) | 44 (33.1) | 36 (28.6) | 26 (28.3) | 0.01 |
| 5 | 2 (6.4) | 20 (15.3) | 27 (21.4) | 17 (18.4) | 0.21 |
| 0 | 0 (0) | 0 (0) | 1 (0.8) | 5 (5.4) | 0.008 |
| 1 | 0 (0) | 0 (0) | 0 (0) | 3 (3.3) | 0.02 |
| 2 | 1 (3.2) | 13 (10.0) | 10 (7.9) | 11 (12.0) | 0.47 |
| 3 | 30 (96.8) | 117 (90.0) | 116 (91.3) | 73 (79.3) | 0.13 |
| Slow flow, n (%) | 2 (6.5) | 18 (13.8) | 14 (11.1) | 20 (21.7) | 0.08 |
| VF, n (%) | 1 (3.2) | 5 (3.8) | 4 (3.2) | 2 (2.2) | 0.92 |
| Application of IABP, n (%) | 0 (0) | 4 (3.1) | 7 (5.6) | 8 (8.7) | 0.15 |
| Administration of β-blocker, n (%) | 22 (71.0) | 98 (75.4) | 81 (64.3) | 50 (54.3) | 0.01 |
| ACEI/ARB, n (%) | 19 (61.3) | 74 (56.9) | 59 (46.8) | 35 (38.0) | 0.02 |
| Administration of diuretic, n (%) | 10 (32.3) | 32 (24.6) | 35 (27.8) | 27 (29.3) | 0.79 |
| Administration of nicorandil, n (%) | 7 (22.6) | 16 (12.3) | 14 (11.1) | 6 (6.5) | 0.11 |
| AKI, n(%) | 3 (9.7) | 8 (6.2) | 7 (5.6) | 15 (16.3) | 0.04 |
| Age, years, mean ± SD | 60.06 ± 15.36 | 60.62 ± 11.44 | 60.14 ± 11.99 | 63.10 ± 11.01 | 0.28 |
| BMI, kg/m2, mean ± SD | 25.62 ± 3.89 | 25.57 ± 3.83 | 25.08 ± 3.34 | 25.41 ± 3.60 | 0.72 |
| Symptom-to-door time, minutes, mean ± SD | 34.94 ± 19.18 | 88.57 ± 39.34 | 137.52 ± 73.03 | 236.72 ± 155.35 | 0.001 |
| P, bpm, mean ± SD | 75.77 ± 17.81 | 76.44 ± 15.94 | 75.53 ± 14.97 | 75.68 ± 19.51 | 0.96 |
| SBP, mmHg, mean ± SD | 131.90 ± 23.90 | 131.43 ± 25.16 | 123.24 ± 23.61 | 119.67 ± 28.76 | 0.002 |
| DBP, mmHg, mean ± SD | 81.61 ± 14.31 | 81.34 ± 13.34 | 76.36 ± 14.48 | 73.25 ± 17.20 | 0.001 |
| Length of lesion, mm, mean ± SD | 24.90 ± 7.35 | 30.55 ± 10.98 | 28.59 ± 9.72 | 29.97 ± 11.62 | 0.04 |
| Syntax score, mean ± SD | 21.26 ± 6.60 | 22.27 ± 8.30 | 22.65 ± 8.06 | 23.94 ± 8.90 | 0.34 |
| WBC, 109/L, mean ± SD | 10.83 ± 4.86 | 10.45 ± 3.04 | 11.07 ± 3.94 | 11.32 ± 3.40 | 0.32 |
| RBC, 1012/L, mean ± SD | 4.64 ± 0.55 | 4.52 ± 0.57 | 4.53 ± 0.65 | 4.48 ± 0.58 | 0.66 |
| HGB, g/L, mean ± SD | 144.85 ± 19.42 | 139.76 ± 17.61 | 141.30 ± 18.20 | 139.14 ± 18.20 | 0.43 |
| PLT, 109/L, mean ± SD | 228.88 ± 53.25 | 218.05 ± 58.11 | 230.72 ± 62.61 | 229.07 ± 67.13 | 0.36 |
| K, mmol/L, mean ± SD | 4.03 ± 0.64 | 4.05 ± 0.47 | 3.99 ± 0.46 | 4.08 ± 0.50 | 0.56 |
| Na, mmol/L, mean ± SD | 138.48 ± 2.76 | 138.54 ± 3.38 | 138.74 ± 3.00 | 139.09 ± 4.15 | 0.67 |
| Cl, mmol/L, mean ± SD | 104.25 ± 2.37 | 102.29 ± 7.23 | 102.30 ± 3.34 | 101.44 ± 8.15 | 0.19 |
| Cr, µmol/L, mean ± SD | 83.60 ± 51.03 | 74.24 ± 20.31 | 74.83 ± 23.76 | 77.63 ± 29.77 | 0.33 |
| UA, µmol/L, mean ± SD | 335.20 ± 94.89 | 307.62 ± 87.65 | 312.18 ± 75.66 | 330.02 ± 105.64 | 0.17 |
| CHOL, mmol/L, mean ± SD | 4.54 ± 1.16 | 4.58 ± 0.97 | 4.61 ± 1.00 | 4.24 ± 1.00 | 0.05 |
| TG, mmol/L, mean ± SD | 1.44 ± 0.73 | 1.55 ± 1.17 | 1.65 ± 1.03 | 1.59 ± 0.79 | 0.71 |
| HDL, mmol/L, mean ± SD | 1.02 ± 0.22 | 1.04 ± 0.24 | 1.03 ± 0.37 | 1.01 ± 0.23 | 0.82 |
| LDL, mmol/L, mean ± SD | 3.03 ± 0.82 | 2.90 ± 0.73 | 2.93 ± 0.74 | 2.81 ± 0.69 | 0.45 |
| CK-MB, ng/mL, mean ± SD | 200.34 ± 108.59 | 185.11 ± 95.02 | 185.27 ± 98.24 | 201.82 ± 104.59 | 0.53 |
| GLU, mmol/L, mean ± SD | 7.56 ± 2.60 | 8.28 ± 3.29 | 8.73 ± 3.67 | 8.84 ± 3.86 | 0.25 |
Continuous variables are presented as mean ± standard deviation and categorical variables as %. ANOVA test (comparison of > 2 groups) for continuous and ordinal variables and the chi-squared test for categorical variables
SBT: symptom to balloon time; BMI: body mass index; DM: diabetes mellitus; LM: left main coronary artery; LAD: left anterior descending coronary artery; LCX: left circumflex branch coronary artery; RCA: right coronary artery; TIMI: thrombolysis in myocardial infarction; IABP: intra-aortic balloon pump, VF: ventricular fibrillation; ACEI: angiotensin-converting enzyme inhibitor, ARB: angiotensin receptor blocker, EF: ejection fraction, CK-MB: creatinine kinase MB; P: pulse; SBP: systolic blood pressure; DBP: diastolic blood pressure; WBC: white blood cell; RBC: red blood cell; HGB: hemoglobin; PLT: blood platelet; K: potassium; Na: sodium; Cl: chlorine; Cr: creatinine; UA: uric acid; CHOL: cholesterol; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; TG: triglycerides; GLU: glucose. P value < 0.05 was considered statistically significant
General characteristics of subjects with the number of EF ≥ 50%
| Characteristic | SBT (minutes) | ||||
|---|---|---|---|---|---|
| ≤ 120 | 121–240 | 241–360 | ≥ 361 | ||
| (n = 90) | (n = 310) | (n = 272) | (n = 118) | ||
| Male, n (%) | 67 (74.4) | 228 (73.5) | 209 (76.8) | 78 (66.1) | 0.18 |
| Smoking history, n (%) | 50 (55.6) | 147 (47.4) | 132 (48.5) | 46 (39.0) | 0.12 |
| Drinking history, n (%) | 27 (30.0) | 79 (25.5) | 76 (27.9) | 31 (26.3) | 0.82 |
| DM history, n (%) | 16 (17.8) | 68 (21.9) | 45 (16.5) | 30 (25.4) | 0.16 |
| Hypertension history, n (%) | 44 (48.9) | 165 (53.2) | 127 (46.7) | 63 (53.3) | 0.39 |
| Myocardial infarction history, n (%) | 6 (6.7) | 15 (4.8) | 16 (5.9) | 6 (5.1) | 0.89 |
| Atrial fibrillation history, n (%) | 0 (0) | 2 (0.6) | 8 (2.9) | 3 (2.5) | 0.08 |
| I | 80 (88.9) | 267 (86.1) | 254 (93.4) | 89 (75.4) | < 0.001 |
| II | 7 (7.8) | 36 (11.6) | 13 (4.8) | 12 (10.2) | 0.03 |
| III | 3 (3.3) | 2 (0.6) | 4 (1.5) | 3 (2.5) | 0.22 |
| IV | 0 (0) | 5 (1.7) | 1 (0.3) | 14 (11.9) | < 0.001 |
| LM, n (%) | 0 (0) | 2 (0.6) | 1 (0.4) | 1 (0.8) | 0.81 |
| LAD, n (%) | 42 (46.7) | 123 (39.7) | 114 (41.9) | 60 (50.8) | 0.17 |
| LCX, n (%) | 10 (11.1) | 51 (16.5) | 29 (10.7) | 11 (9.3) | 0.09 |
| RCA, n (%) | 38 (42.2) | 135 (43.5) | 128 (47.1) | 46 (39.0) | 0.5 |
| 0 | 2 (2.2) | 2 (0.6) | 1 (0.4) | 0 (0) | 0.2 |
| 1 | 1 (1.1) | 7 (2.3) | 3 (1.1) | 2 (1.7) | 0.71 |
| 2 | 5 (5.6) | 22 (7.1) | 36 (13.2) | 7 (5.9) | 0.02 |
| 3 | 31 (34.4) | 119 (38.4) | 119 (43.8) | 51 (43.2) | 0.32 |
| 4 | 47 (52.2) | 121 (39.0) | 66 (24.3) | 35 (29.7) | < 0.001 |
| 5 | 4 (4.5) | 39 (12.6) | 47 (17.2) | 23 (19.5) | 0.006 |
| 0 | 0 (0) | 4 (1.3) | 1 (0.4) | 6 (5.1) | 0.002 |
| 1 | 0 (0) | 3 (1.0) | 1 (0.4) | 5 (4.2) | 0.006 |
| 2 | 2 (2.2) | 16 (5.2) | 8 (2.9) | 8 (6.8) | 0.21 |
| 3 | 88 (97.8) | 287 (92.5) | 262 (96.3) | 99 (83.9) | 0.01 |
| Slow flow, n (%) | 3 (3.3) | 30 (9.7) | 18 (6.6) | 22 (18.6) | 0.001 |
| VF, n (%) | 6 (6.7) | 10 (3.2) | 10 (3.7) | 5 (4.2) | 0.52 |
| Application of IABP, n (%) | 0 (0) | 5 (1.6) | 2 (0.7) | 6 (5.1) | 0.009 |
| Administration of β-blocker, n (%) | 77 (85.6) | 240 (77.4) | 201 (73.9) | 72 (61.0) | 0.001 |
| ACEI/ARB, n (%) | 68 (75.6) | 205 (66.1) | 146 (53.7) | 58 (49.2) | 0.001 |
| Administration of diuretic, n (%) | 15 (16.7) | 64 (20.6) | 58 (21.3) | 24 (20.3) | 0.82 |
| Administration of nicorandil, n (%) | 24 (26.7) | 52 (16.8) | 19 (7.0) | 6 (5.1) | 0.001 |
| AKI, n(%) | 2 (2.2) | 5 (1.6) | 10 (3.7) | 8 (6.7) | 0.062 |
| Age, years, mean ± SD | 59.44 ± 11.13 | 59.77 ± 11.22 | 59.16 ± 12.03 | 61.37 ± 12.08 | 0.38 |
| BMI, kg/m2, mean ± SD | 25.09 ± 2.77 | 25.66 ± 3.22 | 25.44 ± 3.36 | 25.53 ± 2.77 | 0.5 |
| Symptom-to-door time, minutes, mean ± SD | 39.63 ± 23.39 | 82.12 ± 38.93 | 134.06 ± 69.88 | 181.08 ± 138.33 | 0.001 |
| P, bpm, mean ± SD | 75.98 ± 14.76 | 75.67 ± 14.18 | 74.87 ± 17.13 | 76.20 ± 16.65 | 0.85 |
| SBP, mmHg, mean ± SD | 131.54 ± 22.67 | 128.03 ± 22.95 | 129.65 ± 21.90 | 126.66 ± 24.55 | 0.38 |
| DBP, mmHg, mean ± SD | 81.53 ± 15.17 | 78.85 ± 14.53 | 81.03 ± 14.59 | 77.96 ± 14.72 | 0.09 |
| Length of lesion, mm, mean ± SD | 27.49 ± 11.41 | 28.70 ± 10.95 | 28.72 ± 10.36 | 29.09 ± 9.81 | 0.73 |
| Syntax score, mean ± SD | 20.15 ± 7.89 | 20.66 ± 7.83 | 20.24 ± 7.99 | 22.83 ± 9.09 | 0.03 |
| WBC, 109/L, mean ± SD | 9.77 ± 2.76 | 10.77 ± 3.33 | 10.74 ± 3.60 | 11.37 ± 4.38 | 0.02 |
| RBC, 1012/L, mean ± SD | 4.50 ± 0.53 | 4.54 ± 0.61 | 4.49 ± 0.49 | 4.46 ± 0.56 | 0.64 |
| HGB, g/L, mean ± SD | 138.93 ± 17.51 | 138.48 ± 18.01 | 139.05 ± 15.69 | 138.97 ± 17.26 | 0.98 |
| PLT, 109/L, mean ± SD | 229.69 ± 55.36 | 225.93 ± 58.73 | 229.64 ± 63.82 | 233.48 ± 82.61 | 0.73 |
| K, mmol/L, mean ± SD | 3.96 ± 0.40 | 3.94 ± 0.45 | 4.00 ± 0.55 | 4.06 ± 0.46 | 0.11 |
| Na, mmol/L, mean ± SD | 138.43 ± 3.85 | 138.87 ± 3.23 | 139.08 ± 2.96 | 138.86 ± 3.22 | 0.43 |
| Cl, mmol/L, mean ± SD | 104.14 ± 3.77 | 102.92 ± 3.61 | 102.55 ± 5.49 | 102.63 ± 3.31 | 0.02 |
| Cr, µmol/L, mean ± SD | 76.96 ± 20.62 | 72.82 ± 17.51 | 72.53 ± 22.30 | 72.85 ± 28.57 | 0.37 |
| UA, µmol/L, mean ± SD | 329.09 ± 89.98 | 313.02 ± 96.22 | 311.27 ± 84.37 | 308.79 ± 94.02 | 0.38 |
| CHOL, mmol/L, mean ± SD | 4.59 ± 0.97 | 4.59 ± 1.01 | 4.55 ± 0.98 | 4.50 ± 1.07 | 0.83 |
| TG, mmol/L, mean ± SD | 1.82 ± 1.11 | 1.66 ± 1.12 | 1.59 ± 0.91 | 1.78 ± 1.07 | 0.19 |
| HDL, mmol/L, mean ± SD | 1.02 ± 0.25 | 1.04 ± 0.25 | 1.03 ± 0.23 | 0.97 ± 0.20 | 0.06 |
| LDL, mmol/L, mean ± SD | 3.05 ± 0.81 | 2.98 ± 0.92 | 3.01 ± 0.88 | 2.87 ± 0.94 | 0.43 |
| CK-MB, ng/mL, mean ± SD | 163.33 ± 63.29 | 164.41 ± 74.37 | 166.03 ± 47.63 | 177.44 ± 89.39 | 0.31 |
| GLU, mmol/L, mean ± SD | 7.30 ± 3.09 | 8.28 ± 3.43 | 8.12 ± 3.14 | 8.75 ± 3.77 | 0.02 |
Continuous variables are presented as mean ± standard deviation and categorical variables as %. ANOVA test (comparison of > 2 groups) for continuous and ordinal variables and the chi-squared test for categorical variables
SBT: symptom to balloon time; BMI: body mass index; DM: diabetes mellitus; LM: left main coronary artery; LAD: left anterior descending coronary artery; LCX: left circumflex branch coronary artery; RCA: right coronary artery; TIMI: thrombolysis in myocardial infarction; IABP: intra-aortic balloon pump, VF: ventricular fibrillation; ACEI: angiotensin-converting enzyme inhibitor, ARB: angiotensin receptor blocker, EF: ejection fraction, CK-MB: creatinine kinase MB; P: pulse; SBP: systolic blood pressure; DBP: diastolic blood pressure; WBC: white blood cell; RBC: red blood cell; HGB: hemoglobin; PLT: blood platelet; K: potassium; Na: sodium; Cl: chlorine; Cr: creatinine; UA: uric acid; CHOL: cholesterol; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; TG: triglycerides; GLU: glucose. P-value < 0.05 was considered statistically significant
Adjusted odds ratios (with 95% CIs) from logistic regression models for associations of SBT with death
| Models | SBT (min) | P for trend | |||
|---|---|---|---|---|---|
| ≤ 120 | 121–240 | 241–360 | ≥ 361 | ||
| No. of subjects, n | 31 | 130 | 126 | 92 | |
| Death cases, n | 0 | 3 | 9 | 42 | |
| Model 1 | 1 | 1.02 (0.91, 1.14) | 1.03 (1.01, 1.13) | 1.23 (1.08, 1.38) | < 0.001 |
| Model 2 | 1 | 1.05 (0.89, 1.16) | 1.10 (1.02, 1.15) | 1.15 (1.00, 1.47) | 0.15 |
| Model 3 | 1 | 1.03 (1.01, 1.18) | 1.17 (1.03, 1.34) | 1.51 (1.17, 1.54) | 0.01 |
| No. of subjects, n | 90 | 310 | 272 | 118 | |
| Death cases, n | 0 | 8 | 3 | 20 | |
| Model 1 | 1 | 1.05 (0.89,1.28) | 1.15 (1.04, 1.46) | 1.34 (1.12, 1.59) | < 0.001 |
| Model 2 | 1 | 1.04 (0.81, 1.17) | 1.07 (0.82, 1.54) | 1.13 (1.01, 1.73) | 0.09 |
| Model 3 | 1 | 1.01 (0.85, 1.24) | 1.18 (1.01, 2.41) | 1.11 (1.04, 1.94) | 0.08 |
Model 1: Crude model. Model 2: Adjusted for Killip, TIMI and AKI. Model 3: Additionally adjusted for sex, LM, symptom-to-door time, syntax, WBC, CK-MB, β-blocker, ACEI/ARB, BMI, and LDL. P-value < 0.05 was considered statistically significant.